NurExone Biologic Inc.
NRX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 109.34% | 2.62% | 34.66% | 101.45% | -10.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 107.26% | 10.40% | 24.53% | 27.96% | -14.86% |
| Operating Income | -107.26% | -10.40% | -24.53% | -27.96% | 14.86% |
| Income Before Tax | -109.77% | -7.94% | -27.40% | -30.78% | 27.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -109.77% | -7.94% | -27.40% | -30.78% | 27.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.77% | -7.94% | -27.40% | -30.78% | 27.32% |
| EBIT | -107.26% | -10.40% | -24.53% | -27.96% | 14.86% |
| EBITDA | -106.45% | -10.56% | -24.00% | -26.93% | 15.12% |
| EPS Basic | -41.83% | 25.94% | 11.52% | 1.21% | 35.71% |
| Normalized Basic EPS | -43.16% | 25.90% | 11.18% | 0.97% | 36.24% |
| EPS Diluted | -41.83% | 25.94% | 11.52% | 1.21% | 35.71% |
| Normalized Diluted EPS | -43.16% | 25.90% | 11.18% | 0.97% | 36.24% |
| Average Basic Shares Outstanding | 47.21% | 45.93% | 43.48% | 31.90% | 13.15% |
| Average Diluted Shares Outstanding | 47.21% | 45.93% | 43.48% | 31.90% | 13.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |